Teva's Generic Bowel Drug Infringes Patent, Allergan Says

Law360, New York (October 20, 2017, 7:50 PM EDT) -- Allergan USA and Forest Laboratories sued Teva Pharmaceuticals USA Inc. in Delaware federal court on Friday over intellectual property behind the gastrointestinal medicine Linzess.

The drugmakers say that Teva’s generic linaclotide infringes U.S. Patent Number 9,708,371, issued to Forest Labs in July. Linzess is distributed in the U.S. by Allergan, the suit says.

Teva filed an abbreviated new drug application in October 2016 and recently amended it with an attack on Forest Labs' patent, according to the complaint.

“Teva recently amended the Teva ANDA to include,...
To view the full article, register now.